ArticleBlood advances2024

Optimizing the post-CAR T monitoring period in recipients of axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel.

Nausheen Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.